Red Mountain Compounding Recalls Testosterone Cypionate Vials Due to Sterility Concerns
Red Mountain Compounding Pharmacy is recalling specific lots of Testosterone Cypionate 200mg/mL vials because the FDA identified a lack of assurance of sterility.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classification is FDA Class II, and the hazard involves a lack of assurance of sterility in an injectable medication, which poses a significant risk of serious injury or infection.
Plain-English summary
First Royal Care Co. LLC, doing business as Red Mountain Compounding Pharmacy, is recalling specific lots of S-TESTOSTERONE CYP 200MG/ML MDV In SESAME OIL. The product is available in 5ml, 10ml, and 13ml glass vials and is prescription-only. The recall is being conducted due to a lack of assurance of sterility.
The affected product was distributed nationwide in the USA. The recall covers 129 vials across multiple specific lot numbers, including S02252019DH@07, S03202019DT@02, and S07262019DH@06, among others. The expiration dates for these lots range from 8/25/19 to 1/26/20.
Consumers and healthcare providers should check their inventory for the specific lot numbers listed in the recall notice. If the product is found, it should be stopped and returned to the pharmacy or manufacturer for disposal or credit.
The recalled product
- Product
- S-TESTOSTERONE CYP 200MG/ML MDV In SESAME OIL, Rx Only, a) 5ML, b) 10ML, c) 13 ML glass vial, Red Mountain Compounding Rx
- Category
- Drug — Injectable Steroids
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (20)
- Lot #: S02252019DH@07
- Exp 8/25/19
- S03202019DT@02
- EXP
- 8/25/19
- S03212019DT@02
- 9/21/19
- S04232019DT@06
- 10/23/19
- S05232019DT@06
- 11/23/19
- S05152019DH@12
- 11/15/19
- S05242019DT@03
- 11/24/19
- 05152019DH@12
- S06262019DT@02
- 12/26/19
- S07032019DT@12
- 1/3/20
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 100 recalled by First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 100 products in this recall →Related recalls
Same manufacturer · First Royal Care Co. LLC, dba Red Mountain Compounding Pharmacy
See all →- SevereMIT/B12 Compounded Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2021-11-03
- HighTestosterone Ultra 250MG/ML Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2021-11-03
- SevereRed Mountain Compounding Test Cypionate Sterility Assurance Recall
FDA (Drugs) · 2021-11-03
- SevereTEST CYP/PROP Compounded Injection Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2021-11-03
- HighTEST CYP 25MG/ML Injectable Lacks Assurance of Sterility
FDA (Drugs) · 2021-11-03
Same hazard · sterility
See all →- HighFDA recalls injectable compounded mixture in single-use syringes
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- HighTestosterone Cypionate Injectable Recalled for Sterility Assurance Concerns
FDA (Drugs) · 2021-11-03
- SevereTEST CYP 200MG/ML injection recalled due to sterility assurance concerns
FDA (Drugs) · 2021-11-03
- HighWell Care Compounding Pharmacy Recalls Testosterone Cypionate Due to Sterility Concerns
FDA (Drugs) · 2016-06-15
- SevereKey Pharmacy Recalls Testosterone Cypionate Injections Due to Sterility Concerns
FDA (Drugs) · 2017-05-24
- SevereRed Mountain Compounding Test Cypionate Sterility Assurance Recall
FDA (Drugs) · 2021-11-03
- HighFDA Recalls Testosterone Cypionate Injection Vials for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01